Ginkgo Bioworks (DNA) Issues 2021 Revenue Guidance and Business Update

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today preliminary performance updates for the year ended December 31, 2021. Among the results, Ginkgo highlighted that it expects to meet or exceed its key 2021 full year targets for the commencement of new cell programs and revenue from its cell programming and biosecurity offerings based on its preliminary unaudited estimates. The results, along with a broader business review, will be featured in a presentation today at the 40th Annual J.P. Morgan Healthcare Conference.

"In our Q3 earnings call Ginkgo updated our 2021 outlook on the number of new cell programs, Foundry revenue, and Biosecurity revenue — I'm happy to report that based on preliminary unaudited estimates for the full year, we expect to meet or beat all of those, with Biosecurity revenue exceeding our outlook by over 50%," said Jason Kelly, Ginkgo's co-founder and Chief Executive Officer. "Scale is fundamental to our strategy and competitive advantage, and with over $1.6 billion in gross proceeds from our public debut, we believe we are well-positioned to continue to play offense in the coming years. The past year was transformational for Ginkgo, and I am grateful for the dedication of our team and the commitment of our partners in contributing to our success in 2021. I'm excited to work with our team to continue to deliver on our mission and drive rapid growth in the year ahead."

Preliminary 2021 Key Performance Highlights & 2022 Priorities

• Met goal to add at least 30 new programs in 2021, resulting in over 100 cumulative cell programs being launched at Ginkgo.
• Preliminary unaudited Foundry revenue is expected to exceed previously disclosed outlook of $100 million for full year 2021, inclusive of both downstream value share and services revenue.
• Preliminary unaudited Biosecurity revenue is expected to exceed previously disclosed outlook of $110 million for full year 2021 by over 50%.
  • Significant outperformance driven by strong company execution and increasing demand, as schools continue to implement and expand testing programs managed by Concentric, Ginkgo's public health and biosecurity initiative.
  • As evidence of the scale achieved to date, Concentric has recently been collecting over 280,000 samples per week and conducted over 3 million tests in the second half of 2021.
  • Building conviction around long-term development of the biosecurity sector, as exemplified by the U.S. Centers for Disease Control and Prevention (CDC) Travel Biosurveillance Program, where Concentric is collaborating with the CDC and XpresCheck to build an infrastructure that helps identify and mitigate the importation of new and existing pathogens into the United States. Given the success of the program in 2021, the CDC has extended it into 2022.
• Ginkgo continues to have a strong balance sheet, and its capital allocation priorities for 2022 include investments in platform infrastructure and R&D, organizational buildout to support scaling partnerships and public company requirements, and opportunistic external investments, including M&A and licensing opportunities.

Ginkgo expects to report audited fourth quarter and full year 2021 financial results in March 2022, at which time it intends to provide its outlook for full year 2022.

J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

As previously announced, co-founder and CEO Jason Kelly is scheduled to participate in a presentation at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022 at 3:45 p.m. Eastern Time.

Further details, a webcast link, and a replay of the presentation will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.

You May Also Be Interested In

• Equifax (EFX) shares tumble as Q2, full-year guidance falls short
• Old Second Bancorp (OSBC) Reports In-Line Q1 EPS
• Equifax (EFX) Tops Q1 EPS by 6c, Misses on Revenue; Offers Guidance